Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
23.56
+0.21 (0.90%)
Aug 21, 2026, 4:00 PM EDT - Market closed

Nuvectis Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-27.85-26.44-19-22.26-19.09-12.89
Stock-Based Compensation
6.496.034.864.711.711.89
Change in Accounts Payable
0.213.78-0.27-0.141.851.59
Change in Other Net Operating Assets
1.640.632.171.741.97-0.09
Operating Cash Flow
-19.51-16.01-12.25-15.95-13.56-9.5
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
15.3731.2112.0416.4831.88-
Other Financing Activities
-0.49-2.1-0.38-1.39-4.07-
Financing Cash Flow
14.8829.1111.6515.0927.8115.25

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-4.6313.1-0.59-0.8714.255.74

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-8.89-6.83-5.61-7.83-6.12-
Unlevered Free Cash Flow
-8.89-6.83-5.61-7.83-6.12-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1.844.41.91.63.821.49
SEC Filings: 10-K · 10-Q